Goodwin Advises Nurix Therapeutics on Global Collaboration With Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg for $700 Million Upfront and Up to $2.3 Billion in Total

The Life Sciences team advised Nurix Therapeutics, Inc. on a global collaboration with Roche to develop and commercialize bexobrutideg, a potential best-in-class oral degrader of Bruton’s tyrosine kinase (BTK). The partnership brings together Nurix’s pioneering expertise in targeted protein degradation and Roche’s proven portfolio of B-cell targeted therapies and global clinical and commercial infrastructure.

Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory, and sales milestones for potential total payments of up to $2.3 billion. Development costs will be shared 40% by Nurix and 60% by Roche. The parties will equally split the profits and losses from US commercialization. Nurix and Roche will co-commercialize bexobrutideg in the United States across all indications. Outside of the United States, Roche will be responsible for commercialization, with Nurix eligible to receive royalties ranging from the low- to high-teens.

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines. Nurix’s lead program, bexobrutideg, a potential best-in-class oral BTK degrader, is being developed in a global collaboration with Roche across malignant hematology, immunology, and neurology. Nurix’s pipeline includes multiple additional wholly owned programs as well as partnered programs under collaboration agreements with Gilead Sciences, Sanofi, and Pfizer, within which Nurix retains certain options for co-development, co-commercialization, and profit sharing. Powered by its proprietary AI-integrated DEL-AI discovery engine and deep E3 ligase expertise, Nurix is advancing targeted protein degradation as the next frontier in drug development. Nurix is headquartered in Brisbane, California.

The Goodwin team was led by Adam Bellack, Sarah Stoiber, Lucy Charlton, Georgia Powell, Kelly Song, Bonnee Nie, Alan Wang, Paul Jin, Ortal Ben Aharon, Arom Yun, Dan Karelitz, and Elizabeth Mulkey.

For more information on the deal, please read the press release.